1-64884134-C-G
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_002227.4(JAK1):c.7-659G>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.372 in 151,880 control chromosomes in the GnomAD database, including 13,224 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.37 ( 13224 hom., cov: 31)
Consequence
JAK1
NM_002227.4 intron
NM_002227.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.270
Publications
4 publications found
Genes affected
JAK1 (HGNC:6190): (Janus kinase 1) This gene encodes a membrane protein that is a member of a class of protein-tyrosine kinases (PTK) characterized by the presence of a second phosphotransferase-related domain immediately N-terminal to the PTK domain. The encoded kinase phosphorylates STAT proteins (signal transducers and activators of transcription) and plays a key role in interferon-alpha/beta, interferon-gamma, and cytokine signal transduction. This gene plays a crucial role in effecting the expression of genes that mediate inflammation, epithelial remodeling, and metastatic cancer progression. This gene is a key component of the interleukin-6 (IL-6)/JAK1/STAT3 immune and inflammation response and is a therapeutic target for alleviating cytokine storms. The kinase activity of this gene is directly inhibited by the suppressor of cytokine signalling 1 (SOCS1) protein. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2020]
JAK1 Gene-Disease associations (from GenCC):
- autoinflammation, immune dysregulation, and eosinophiliaInheritance: AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae)
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.94).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.64 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.371 AC: 56370AN: 151760Hom.: 13169 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
56370
AN:
151760
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.372 AC: 56500AN: 151880Hom.: 13224 Cov.: 31 AF XY: 0.374 AC XY: 27735AN XY: 74242 show subpopulations
GnomAD4 genome
AF:
AC:
56500
AN:
151880
Hom.:
Cov.:
31
AF XY:
AC XY:
27735
AN XY:
74242
show subpopulations
African (AFR)
AF:
AC:
26759
AN:
41372
American (AMR)
AF:
AC:
5362
AN:
15256
Ashkenazi Jewish (ASJ)
AF:
AC:
1060
AN:
3470
East Asian (EAS)
AF:
AC:
3064
AN:
5146
South Asian (SAS)
AF:
AC:
1694
AN:
4812
European-Finnish (FIN)
AF:
AC:
2720
AN:
10554
Middle Eastern (MID)
AF:
AC:
70
AN:
294
European-Non Finnish (NFE)
AF:
AC:
14841
AN:
67958
Other (OTH)
AF:
AC:
742
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1561
3121
4682
6242
7803
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
1770
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.